QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
NASDAQ:OVID

Ovid Therapeutics Stock Forecast, Price & News

$3.14
+0.10 (+3.29%)
(As of 01/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.04
$3.18
50-Day Range
$3.04
$3.64
52-Week Range
$2.50
$4.80
Volume
224,727 shs
Average Volume
199,233 shs
Market Capitalization
$213.81 million
P/E Ratio
1.75
Dividend Yield
N/A
Beta
1.68
30 days | 90 days | 365 days | Advanced Chart
Receive OVID News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Ovid Therapeutics logo

About Ovid Therapeutics

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Headlines

Xenon draws buyout speculation after Zogenix deal
January 19, 2022 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OVID
Fax
N/A
Employees
67
Year Founded
N/A

Sales & Book Value

Annual Sales
$12.62 million
Book Value
$0.69 per share

Profitability

Net Income
$-81.04 million
Pretax Margin
60.01%

Debt

Price-To-Earnings

Miscellaneous

Free Float
60,057,000
Market Cap
$213.81 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/20/2022
Next Earnings (Estimated)
3/21/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.14 out of 5 stars

Medical Sector

467th out of 1,415 stocks

Pharmaceutical Preparations Industry

219th out of 682 stocks

Analyst Opinion: 3.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -












Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

Is Ovid Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Ovid Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares.
View analyst ratings for Ovid Therapeutics
or view top-rated stocks.

How has Ovid Therapeutics' stock been impacted by COVID-19?

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OVID shares have increased by 17.2% and is now trading at $3.14.
View which stocks have been most impacted by COVID-19
.

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Ovid Therapeutics
.

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) posted its earnings results on Wednesday, November, 10th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.02.
View Ovid Therapeutics' earnings history
.

What price target have analysts set for OVID?

5 equities research analysts have issued 12 month price targets for Ovid Therapeutics' shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate Ovid Therapeutics' share price to reach $4.50 in the next year. This suggests a possible upside of 43.3% from the stock's current price.
View analysts' price targets for Ovid Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the following people:
  • Jeremy Max Levin, Chairman, President & Chief Executive Officer
  • Jason Tardio, Chief Operating Officer
  • Jeffrey A. Rona, Chief Financial, Accounting & Business Officer
  • Claude Nicaise, Head-Research & Development
  • Julia Tsai, Senior VP-Clinical Development & Medical Affairs

What other stocks do shareholders of Ovid Therapeutics own?

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

How do I buy shares of Ovid Therapeutics?

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $3.14.

How much money does Ovid Therapeutics make?

Ovid Therapeutics has a market capitalization of $213.81 million and generates $12.62 million in revenue each year. The company earns $-81.04 million in net income (profit) each year or $1.79 on an earnings per share basis.

How many employees does Ovid Therapeutics have?

Ovid Therapeutics employs 67 workers across the globe.

What is Ovid Therapeutics' official website?

The official website for Ovid Therapeutics is www.ovidrx.com.

Where are Ovid Therapeutics' headquarters?

Ovid Therapeutics is headquartered at 1460 Broadway Suite 15044, New York NY, 10036.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at (646) 661-7661 or via email at [email protected].


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.